Pathos AI Secures $237 Million for Drug Development

The company secured funding led by Bristol Myers Squibb to advance AI-driven neurological research.

Updated on Oct. 23, 2026 in Alzheimer’s

Pathos AI Secures $237 Million for Drug Development

Live Poll

Do you believe increased AI integration in pharmaceutical research will lead to better medical outcomes?

Pathos AI has closed a $237 million series E funding round led by Bristol Myers Squibb. The capital will support the expansion of its Foundry AI platform to accelerate drug discovery.

Why it matters

By integrating artificial intelligence into clinical asset identification, Pathos AI aims to increase the probability of success in complex drug development programs. This strategic move includes a focus on Alzheimer's disease research through new industrial partnerships.

This series E round follows previous funding, including $365 million raised in May 2025 and $62 million in October 2024. Additionally, Pathos AI has signed a five-year contract valued at $55 million with Tempus AI to generate neurological datasets.

The players

Pathos AI

A biotechnology company that leverages artificial intelligence to identify and develop clinical assets.

Bristol Myers Squibb

A global biopharmaceutical company that focuses on discovering and developing innovative medicines for serious diseases.

Tempus AI

A technology company that utilizes big data and artificial intelligence to advance precision medicine.

The details

The firm utilizes its Foundry AI platform to track drug program data from genomics to competitive market factors. The newly formed partnership with Tempus AI will focus on creating a massive dataset from hundreds of thousands of patients to guide adaptive clinical trials.

October 2024: Pathos AI raised $62 million in a series C funding round.
May 2025: The company secured $365 million in a series D funding round.
October 22, 2026: Details regarding the Foundry platform intelligence capabilities were released.
October 23, 2026: Pathos AI finalized its series E round and signed the Bristol Myers Squibb collaboration.

The Big Picture

The Foundry AI platform represents a shift toward using predictive software to manage drug discovery pipelines from initial genomics to market positioning. This development follows a broader trend in the pharmaceutical industry to replace traditional, slower research cycles with AI-assisted adaptive trials.

The collaboration aims to accelerate the development of new treatments for neurological conditions, potentially expanding future therapeutic options for patients. While these developments are early-stage, the improved identification of drug candidates may lead to more effective clinical outcomes in the coming years.

The takeaway

Investment in AI-driven platforms is increasingly becoming a standard strategy for biotech firms seeking to mitigate the high risks associated with drug development. These partnerships highlight how data-rich environments are being leveraged to refine clinical trial designs and target specific diseases more precisely.